CSM Advisors LLC Buys Shares of 560 Stryker Co. (NYSE:SYK)

by · The Cerbat Gem

CSM Advisors LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 560 shares of the medical technology company’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker during the fourth quarter valued at approximately $25,000. Rakuten Securities Inc. increased its stake in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in Stryker in the 4th quarter worth $30,000. BankPlus Trust Department purchased a new position in Stryker during the fourth quarter valued at $33,000. Finally, VSM Wealth Advisory LLC bought a new stake in Stryker during the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on SYK shares. Argus set a $450.00 price objective on Stryker in a research report on Monday, February 3rd. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a “buy” rating in a report on Monday, April 14th. Finally, Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $423.53.

Check Out Our Latest Report on SYK

Stryker Stock Performance

Shares of NYSE:SYK opened at $348.62 on Wednesday. The firm has a fifty day simple moving average of $369.25 and a two-hundred day simple moving average of $373.06. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $133.06 billion, a P/E ratio of 44.93, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. On average, analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.96%. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).